Market Demand and Product Development - The medical rehabilitation field has a pressing demand for brain-machine interfaces, particularly for patients with paralysis and epilepsy [2] - The company is primarily engaged in neurosurgery, offering Class III medical devices such as artificial dura mater patches and craniofacial repair systems [2] Financial Performance - In the first half of 2025, the sales revenue from dura mater products reached CNY 71.36 million, a year-on-year increase of 3.24% [3] - The sales revenue from absorbable regenerated cellulose and dura mater medical glue totaled CNY 38.32 million, marking a significant growth of 169.66% compared to the previous year [4][7] - Overseas revenue for the company reached CNY 38.10 million, reflecting a growth of 50.96% year-on-year [8] Strategic Collaborations and Innovations - The company has established deep collaborations with top research institutions like Tsinghua University, which provides a strong opportunity for entering the brain-machine interface field [2] - The company’s self-developed dura mater medical glue, Ruigu, was launched in February 2023 and has received MDR certification, allowing for legal sales in EU markets [5][7] Market Trends and Challenges - The overall market size for craniofacial repair and fixation in China reached CNY 1.75 billion in 2023, with a compound annual growth rate (CAGR) of 15.3% from 2018 to 2023, indicating significant replacement potential for traditional materials [3] - Challenges in replacing traditional titanium materials with PEEK include high technical barriers and the need for clinical acceptance [3] Future Outlook - The company plans to expand its market share in domestic and international markets by enhancing its neurosurgery solutions and increasing brand influence [8] - The company is actively pursuing the acquisition of a medical technology firm to broaden its capabilities in bio-synthetic materials [6]
迈普医学(301033) - 2025年9月19日投资者关系活动记录表